AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

THE OCCURRENCE OF ARRHYTHMIAS IN VASCULAR HEART DISEASES AND MEASURES TO OPTIMIZE THEIR TREATMENT

Sokhib Rashidov Zamon o'g'li
Davronbek A'zamov Salim o'g'li
Zukhriddin O‘rishboev Alisher o‘g‘li
Department of the pharmacology of the Tashkent state medical university

Abstract. Millions of people worldwide suffer from cardiac arrhythmias, which are a group of disorders marked by irregular heartbeats that greatly increase morbidity and mortality. The definition, categorization, epidemiology, and vital significance of efficient management of cardiac arrhythmias are all covered in this study, which offers a thorough examination of current procedures and new treatments in this area. It investigates the pathophysiology of different arrhythmias, including arrhythmogenesis mechanisms including triggered activity, automaticity, and re-entry. In addition to discussing the clinical presentation of various arrhythmias, ranging from supraventricular to ventricular kinds and bradyarrhythmias, the review covers the most recent diagnostic techniques, such as electrophysiological tests, Holter monitoring, and ECG. We analyze the effectiveness and limitations of current pharmacological and non-pharmacological treatment approaches, such as antiarrhythmic medications, catheter ablation, and device therapy; additionally, the review explores novel antiarrhythmic agents, gene therapy, advanced catheter ablation techniques, and cutting-edge device technologies, such as leadless pacemakers and subcutaneous implantable cardioverter-defibrillators (ICDs); special considerations for managing arrhythmias in a variety of populations, such as children, the elderly, and pregnant women. The review also looks at the future of arrhythmia care, with a focus on applications of artificial intelligence, customized medicine, and the use of cutting-edge technologies in detection and therapy. In order to improve patient outcomes with cardiac arrhythmias, this study attempts to improve understanding and encourage improvements in the field by integrating current knowledge and prospects.

Keywords. Atrial fibrillation, cardiac arrhythmias, electrophysiology, antiarrhythmic medications, catheter ablation, novel treatments.

Introduction. Hippocrates is credited with describing sudden cardiac death in otherwise healthy patients who frequently have severe fainting episodes. Long-QT syndrome, arrhythmogenic right ventricular dysplasia or cardiomyopathy (Naxos disease), Brugada syndrome, and hypertrophic cardiomyopathy are some of the electrical diseases that contribute to this condition. Premature ventricular beats and other features of left and right ventricular contraction were not described until the 19th century by Étienne-Jules Marey. Recently, there has been discussion of historical aspects of cardiac electrophysiology. Developing new pharmacologic or non-pharmacologic treatments requires a deeper comprehension of the physiopathology of cardiac arrhythmias at the subcellular and cellular levels, especially the differentiation between ventricular arrhythmias and atrial fibrillation. Heart arrhythmias are abnormal heart rhythms caused by problems with the electrical system of the heart [1-5]. These anomalies may show up as aberrant conduction pathways, heart rate, or rhythm. Arrhythmias can be broadly divided into two groups: bradyarrhythmias, which are defined by an unusually slow heart rate (less than 60 beats per minute), and tachyarrhythmias, which are characterized by an abnormally high heart rate (more than 100 beats per minute). Ventricular arrhythmias, which

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

originate inside the ventricles, and supraventricular arrhythmias, which originate above the ventricles, are subcategories. Atrial fibrillation (AF), atrial flutter, supraventricular tachycardia (SVT), ventricular tachycardia (VT), and ventricular fibrillation (VF) are common forms of arrhythmias. Millions of people worldwide suffer from cardiac arrhythmias. The most prevalent kind, atrial fibrillation, affects an estimated 33 million people worldwide [6-11]. Arrhythmias are more common in those with underlying cardiovascular conditions like heart failure, coronary artery disease, and hypertension, and their occurrence rises with age. Additionally, groups with certain risk factors, such as obesity, diabetes, and a sedentary lifestyle, have a higher prevalence of arrhythmias. The incidence of cardiac arrhythmias is on the rise due to the aging population and the prevalence of cardiovascular risk factors. Because cardiac arrhythmias have the potential to significantly increase morbidity and death, effective care of these conditions is essential. Severe consequences include heart failure, stroke, and abrupt cardiac death can result from untreated arrhythmias. For example, atrial fibrillation increases the risk of stroke by five times and is a key risk factor. One of the main causes of death, sudden cardiac arrest, can result from ventricular arrhythmias, especially ventricular fibrillation. Effective management can raise survival rates, lower the risk of complications, and improve quality of life. An in-depth analysis of contemporary procedures and cutting-edge treatments for the treatment of cardiac arrhythmias is the goal of this thorough assessment. Atrial fibrillation, a common cardiac arrhythmia in clinical practice, is primarily produced by structural and electrical changes in atrial tissues [12-17]. It is a supraventricular tachyarrhythmia that results from uncoordinated atrial activation and atrial mechanical dysfunction. Although it can occur in the absence of underlying cardiac illness, it is more commonly associated with heart failure, ischemic heart disease, hypertension, and mitral valve disease. Pharmaceuticals can be used to regulate atrial fibrillation's early symptoms. Treatment aims to enhance survival, lower the risk of stroke, restore atrial functions, reverse ultrastructural remodeling, and alleviate symptoms. Atrial fibrillation is typically asymptomatic, unnoticed, and self-terminating, but ventricular arrhythmias are typically disastrous and necessitate prompt care. However, atrial fibrillation can progress from paroxysmal to chronic over time, making therapeutic therapies more challenging. To put it another way, as the illness worsens, both triggers and contributing factors alter. The main factors that influence the progression of atrial fibrillation at different stages have been identified. For instance, the atrial myocardium becomes more susceptible to reentrant circuit formation, action potential and refractory period duration shortening, conduction slowing, and a lower threshold for alternans induction (a critical component for vulnerable substrate generation) due to significant electrical and structural remodeling, altered conduction, and refractoriness [18-24]. Although further structural and functional information is required, ultrastructural changes at the level of the atrial cardiomyocyte membrane most likely contribute to the pathophysiology of atrial fibrillation. Every alteration to the structure of atrial tissue has a significant impact on tissue conductivity, wave propagation, and reentry potential. The development of clinical strategies to enhance patients' quality of life has been made possible by basic science and clinical research. The experimental and clinical developments that are essential to the clinical management of cardiac arrhythmias are examined here. Using the search terms cardiac arrhythmias, ischemic heart disease, electrophysiology, intrinsic cardiac nervous system, pharmacological treatments, implantable cardioverter defibrillator, catheter ablation, ischemic preconditioning, and combinations of these, we searched English-language clinical and basic science reports on the PubMed and Google Scholar platforms for this review [25-30]. By examining the most recent developments and therapeutic techniques, this review aims to educate medical practitioners about the best methods for identifying and treating these complicated illnesses. The study will

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

highlight the changing field of managing cardiac arrhythmias by covering the pathogenesis, clinical presentation, diagnostic methods, and current and emerging therapeutic options. In order to improve patient outcomes and solve the difficulties related to cardiac arrhythmias, we hope that this review will highlight the significance of ongoing research and innovation [31-36].

The main purpose of the presented manuscript is to provide a brief commentary on the results of reputable scientific papers on the occurrence of arrythmias in vascular heart diseases and measures to optimize their treatment.

General guidelines. In mammalian hearts, cardiac activity depends on rhythmic contraction regulated by specialized cardiac pacemaker cells. Cardiomyocytes and other cell types work in concert with a well-established electrical conduction system (such as the His bundle, the right and left bundle branches, the fascicles, the Purkinje fibers, and the sinoatrial and atrioventricular nodes) to regulate heart function in an organized manner. The highly coordinated action (i.e., opening, closing, and inactivation) of plasma membrane ion channel proteins is necessary for cardiac action potentials; conduction is mediated by gap junctions and relies on electrical connection between various cell types. According to Larson and colleagues, the human cardiac action potential has five distinct phases (0–4). Phase 0 involves stimulation from the sinoatrial node, which further raises the atrial myocytes' membrane potential to a threshold. This opens voltage-activated sodium channels, as sodium ions diffuse along an electrochemical gradient (from the extracellular space, across the plasma membrane, and into the cell) [4-11]. The majority of the available sodium currents stay in reserve because the sodium current creates a positive feedback loop. A lengthy plateau (caused by equilibrium between inward (such as L-type calcium, sodium-calcium exchanger) and outward (such as potassium—both delayed and inward rectifying) currents) follows rapid repolarization caused by quick and slow transient outward potassium currents (phase 1). Because the membrane potential and the potassium Nernst potential diverge, there is a strong pushing force for potassium efflux during this period. Phase 3 involves the inactivation of calcium currents and the repolarization caused by outgoing potassium currents, which directs the membrane potential toward potassium equilibrium. Following total repolarization, the membrane potential recovers to resting levels in phase 4. A variety of voltage-gated ion channel pore-forming subunits are expressed by mammalian cardiomyocytes. These subunits help create inward and outward currents that impact automaticity and refractoriness as well as action potential waveforms. Ventricular action potential waveforms are significantly impacted by the interaction of all the ionic currents. Studies using molecular genetics have shed light on these linkages [21-28].

Medication. Based on ionic channel participation and effects on action potential, sinus node function, and atrioventricular conduction, the Vaughan Williams classification system is commonly used to categorize the wide range of anti-arrhythmic medications (see the current review by Larson et al.). Class I medicines inhibit the rapid inward sodium current, which causes cardiac depolarization and conduction as well as prolonged repolarization. They have a wide range of actions that target blocking of sodium channels. Additionally, they impact action potential and the length of the effective refractory period, which in turn affects automaticity. Beta blockers and other class II drugs work by reducing sympathetic activity, which lowers the action potential's initial depolarization rate and lessens automaticity and conduction velocity. Some studies dispute the idea that using beta-blockers to treat arrhythmias can lower a patient's risk of sudden death. However, in clinical trials, combination therapy—which combines beta-blockade drugs with implanted cardiac defibrillators—offers notable advantages [7-14]. Potassium channel blockers, or class III drugs, primarily work by obstructing the delayed rectifier potassium channel, which prolongs repolarization. Class IV drugs, often known as

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

calcium channel blockers, mainly work at the atrioventricular node level by obstructing slow inward Ca currents. This prolongs the effective refractory time with no impact on the His-Purkinje system or cardiomyocytes. Calcium channel blockers are thought to be a helpful adjunctive treatment for catecholaminergic polymorphic ventricular tachycardia (inherited tachycardia in structurally normal hearts during increased sympathetic activity) and idiopathic left ventricular tachycardia, despite their limited effectiveness for the majority of ventricular tachycardia types [31-39].

Interventions without pharmaceuticals. Antiarrhythmic medications are the mainstay of first-order treatment for heart arrhythmias in patients. Nevertheless, there is little data to support pharmacotherapy's overall effectiveness. Interventions like catheter ablation, cardioverter defibrillators, and implantable electronic pacemakers have been developed as a result. In the 1930s, cardiac pacing—that is, electrical stimulation to alter heart mechanical activity—was first used in therapeutic settings. The standard treatment for symptomatic bradycardia-related symptoms brought on by atrioventricular node block or sinus node dysfunction, as well as severe left ventricular dysfunction, is an electronic pacemaker device (either unipolar or bipolar) that delivers an electrical pulse strong enough to depolarize myocardium (i.e., stimulation threshold) [9-16]. To properly treat patients' symptoms (delayed/absent activation of the whole ventricle), characteristics like pulse amplitude and duration must be optimized. According to retrospective clinical data, ablation is significantly more successful than traditional medication in treating cardiac arrhythmias. A number of clinical trials have shown that catheter ablation is superior in patients who are not responding to medication, and recent guidelines recommend that it be used for recurrent paroxysmal atrial fibrillation. The cardiac autonomic nervous system, which controls heart rate and cardiac output in response to different physiological situations, is made up of intrinsic (network of intracardiac ganglia and connecting neurons) and extrinsic (vagus nerve) components [21-29]. Clinical and experimental research has revealed effective non-pharmacologic preventive measures against deadly arrhythmias caused by ischemia-reperfusion damage. Ischemic conditioning has been shown to: 1) prevent cellular necrosis; 2) maintain post-ischemic cardiac function; and 3) lower the incidence of cardiac arrhythmias. It involves short episodes of repeated arterial occlusion/reperfusion performed before a longer episode of arterial occlusion. It is unknown if the overall protection against tissue damage is connected to the antiarrhythmic protection provided by ischemia conditioning [32-38].

Viewpoints. Clinical practitioners' access to better diagnostic tools and detection techniques may help to explain the rising global prevalence of cardiac arrhythmias and its effects. According to estimates, cardiac arrhythmias impact over 2% of the world's population and carry a significant socioeconomic cost. Recent research on the pathophysiology of cardiac arrhythmias and various approaches to their therapeutic management are presented in this review article. The underlying etiology of an arrhythmia determines the course of treatment. Medication is necessary in certain situations, while more intrusive techniques like electrical cardioversion, catheter ablation, or pacemaker or defibrillator installation are needed in others. Reversing the processes linked to electrical and structural modeling that sustain cardiac arrhythmias is crucial because the ultimate goal of treatment is to restore normal sinus rhythm [23-29]. Nonetheless, it is becoming more and more evident that the effectiveness of medications alone in treating cardiac arrhythmias is constrained. Significant efforts are therefore being made to identify appropriate substitutes; combination therapy utilizing pharmaceutical and non-pharmacologic therapies shouldn't be disregarded. It is necessary to identify the risk factors that contribute to the pathophysiology of cardiac arrhythmias. The pathophysiology of cardiac arrhythmias also requires a greater focus on sex and gender differences; significant electrophysiologic disparities

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

between men and women in an aging population have long been documented. The incidence and significance of risk factors and the etiology of cardiac arrhythmias differ significantly between sexes and genders, according to current evidence. Lastly, there is a lack of clarity regarding physiological differences and their origin. However, the therapeutic treatment of all patients with cardiac arrhythmias may be significantly impacted by knowledge of sex and gender issues. Which genetic or non-genetic pathways need to be investigated in order to inform future treatment plans for the primary and secondary prevention of cardiac arrhythmias? To find new targets for therapeutic (and perhaps customized) treatment of cardiac arrhythmias, further translational and epidemiologic research is required [30-39].

Prospective paths and investigations. Significant progress in the treatment of cardiac arrhythmias is anticipated in the future, especially in the area of customized medicine. This method places a strong emphasis on customizing treatment plans for each patient according to their particular genetic, environmental, and lifestyle characteristics. Healthcare professionals will be able to detect particular genetic variations linked to arrhythmias when genetic testing becomes more widely available and reasonably priced. This information can help choose antiarrhythmic drugs and therapies that are most likely to work for each patient.Additionally, proactive risk assessment can be facilitated by linking genetic data with electronic health records. This enables clinicians to identify patients who are more susceptible to arrhythmias and to initiate preventive interventions early in life. Another exciting area is the application of machine learning (ML) and artificial intelligence (AI) to the treatment of arrhythmias. Large volumes of data from Holter monitors, implanted devices, and ECGs can be analyzed by AI and ML algorithms to increase the speed and accuracy of diagnosis [3-13]. In order to enable prompt therapies, these technologies can also create prediction models that identify patients who are at high risk for arrhythmias. AI can also improve procedure results by optimizing catheter ablation techniques through patient-specific data analysis. As these technologies advance, they will offer a more sophisticated comprehension of arrhythmias, resulting in more accurate and customized therapy regimens. In order to provide equitable healthcare for all patients, it is imperative to address gaps in access to arrhythmia care. Reaching underprivileged groups and giving them access to the treatment and resources they need can be achieved through the expansion of telehealth services and remote monitoring. Patients from a variety of backgrounds can be empowered to actively participate in their care by creating shared decision-making tools and culturally appropriate patient education materials. In order to guarantee that precision medicine approaches are applicable to a wide range of populations, it is also essential to promote diversity in clinical trials. We can fight to remove obstacles to care and improve outcomes for everyone impacted by cardiac arrhythmias by supporting laws that increase insurance coverage and the cost of cutting-edge tests and treatments [27-36].

Discussion. A synchronized heartbeat depends on the electrical conduction system of the heart. The bundle of His and Purkinje fibers, the atrioventricular (AV) node, and the sinoatrial (SA) node are some of its essential parts. Every heartbeat is started by electrical impulses produced by the right atrium's SA node, which serves as the heart's natural pacemaker. The atria contract and force blood into the ventricles as a result of these impulses propagating across the atrial myocardium. After that, the AV node receives the electrical signal, which is momentarily delayed to enable full ventricular filling. After this delay, the impulse enters the Purkinje fibers via the bundle of His, which disperses the electrical signal throughout the ventricles and causes them to contract. Coordinated activation of ion channels and transporters that enable well-ordered electrical impulse propagation across the myocardium is necessary for maintaining a regular heart rhythm [4-12]. Heart arrhythmias that might be fatal in certain patients are caused

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

by disturbances in this regular mechanism. The presence of structural cardiac disease brought on by myocardial infarction (because of the creation of fibrotic scars) or left ventricular dysfunction significantly increases the risk of common acquired arrhythmias. Genetic variations affect the myocardial substrate's excitability or structure, making patients more susceptible to arrhythmias. Similar to this, different subgroups within the population that influence particular drug biotransformation reactions are created by genetic polymorphisms of drug-metabolizing enzymes. However, determining the triggers that cause or sustain cardiac arrhythmias is still a difficult task. The physiopathology of inherited and acquired cardiac arrhythmias is summarized below, along with the pharmacologic and non-pharmacologic treatments that are utilized to reduce their impact on morbidity and possible fatality. Since the incidence of cardiac arrhythmias is rising globally, better knowledge of the molecular and cellular aspects of arrhythmogenesis as well as more epidemiologic studies (for a more accurate portrait of incidence and prevalence) are essential for the development of novel treatments and for managing cardiac arrhythmias and their consequences in patients [15-22]. The heart beats in unison because to its extremely well-organized conduction system, which facilitates effective blood circulation throughout the body. Arrhythmias are mainly classified into aberrant impulse initiation and impulse conduction, albeit they can result from a variety of processes. When pacemaker cells outside the SA node produce electrical impulses on their own, usually as a result of modifications in membrane potential, this is known as abnormal automaticity. Another way that early or delayed afterdepolarizations cause extra impulses that throw off the regular rhythm is through triggered activity. Future studies must focus on quality of life and long-term results after arrhythmia treatments. It is crucial to assess how different treatment approaches, including drugs, catheter ablation, and implantable devices, affect patients' symptoms, functional state, and general well-being. Clinicians can more effectively customize treatments to meet the needs of each patient by determining predictors of positive results. Additionally, using patient-reported outcome measures will guarantee that the patient's opinion is at the forefront of assessing the efficacy of treatment, which will eventually improve the quality of life for those with arrhythmias [27-35].

Conclusion. The committee concluded that the arrhythmias listing should be changed to allow claimants to meet the listing with objective diagnosis of recurrent (as defined by SSA) episodes of tachycardia or bradycardia that cause cardiac syncope, near syncope, or other incapacitating symptoms, confirmed by ECG or other appropriate medically acceptable testing, after reviewing the most recent medical literature and relevant American College of Cardiology/American Heart Association treatment and practice guidelines. A documented arrhythmia should occur at the same time as symptoms that significantly impair the patient's capacity to commence, maintain, or finish instrumental or everyday life activities on their own. Additionally, the symptoms and arrhythmia must persist in spite of the recommended course of treatment. The claimants' medical documents should demonstrate that the arrhythmia has no reversible cause, just like in the existing listing.

In conclusion, managing cardiac arrhythmias is a dynamic and rapidly evolving field, encompassing various diagnostic and therapeutic approaches. From traditional pharmacological treatments and electrical interventions to cutting-edge techniques like catheter ablation and novel device therapies, the landscape of arrhythmia management continues to advance, driven by ongoing research and technological innovations. Emerging therapies, including gene therapy and AI-driven diagnostics, hold promise for more personalized and effective treatment strategies. In order to lower the morbidity and mortality linked to arrhythmias, a concentrated effort must be made to improve current therapies and create novel approaches. To address the difficulties in managing arrhythmias, optimize patient outcomes, and improve the quality of life for patients

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

afflicted by these potentially fatal conditions, more research, innovation, and clinical trials are required.

References.

1. Nagpal AK, Pundkar A, Singh A, Gadkari C. Cardiac Arrhythmias and Their Management: An In-Depth Review of Current Practices and Emerging Therapies. Cureus. 2024 Aug 9;16(8):e66549. doi: 10.7759/cureus.66549.
2. Kingma J, Simard C, Drolet B. Overview of Cardiac Arrhythmias and Treatment Strategies. Pharmaceuticals. 2023; 16(6):844. https://doi.org/10.3390/ph16060844
3. Institute of Medicine (US) Committee on Social Security Cardiovascular Disability Criteria. Cardiovascular Disability: Updating the Social Security Listings. Washington (DC): National Academies Press (US); 2010. 13, Arrhythmias. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209966/
4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
5. Chojnacki, C.; Konrad, P.; Błońska, A.; Medrek-Socha, M.; Przybylowska-Sygut, K.; Chojnacki, J.; Poplawski, T. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth. Nutrients 2022, 14, 3217.
6. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
7. Socała K., Doboszewska U., Szopa A., Serefko A., Włodarczyk M., Zielińska A., Poleszak E., Fichna J., Wlaź P. The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders. Pharmacol. Res. 2021;172:105840. doi: 10.1016/j.phrs.2021.105840.
8. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
9. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
10. Góralczyk-Bińkowska, A.; Szmajda-Krygier, D.; Kozłowska, E. The Microbiota–Gut–Brain Axis in Psychiatric Disorders. Int. J. Mol. Sci. 2022, 23, 11245.
11. Heiss C.N., Olofsson L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.
12. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг

гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
13. Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
14. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
15. Guerra E., Garcia-Sanchez Y., Jornet-Gibert M., Nuñez J., Balaguer-Castro M., Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2022;54((Suppl. S3)):S26–S29. doi: 10.1016/j.injury.2022.01.047.
16. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
17. Asahina Y., Wurtz N.R., Arakawa K., Carson N., Fujii K., Fukuchi K., et al. Discovery of BMS-986235/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure. J. Med. Chem. 2020;63(17):9003–9019. doi: 10.1021/acs.jmedchem.9b02101.
18. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
19. Patton E.E., Zon L.I., Langenau D.M. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat. Rev. Drug Discov. 2021;20:611–628. doi: 10.1038/s41573-021-00210-8.
20. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
21. Stokes, J.M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N.M.; MacNair, C.R.; French, S.; Carfrae, L.A.; Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. Cell 2020, 180, 688–702.e613.
22. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06
23. Thafar, M.A.; Alshahrani, M.; Albaradei, S.; Gojobori, T.; Essack, M.; Gao, X. Affinity2Vec: Drug-target binding affinity prediction through representation learning, graph mining, and machine learning. Sci. Rep. 2022, 12, 4751.
24. Sokhib Rashidov Zamon o'g'li, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o'g'li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856

25. Lozano-Velasco, E.; Franco, D.; Aranega, A.; Daimi, H. Genetics and Epigenetics of Atrial Fibrillation. Int. J. Mol. Sci. 2020, 21, 5717.
26. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
27. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
28. Kong Y.K., Song K.-S., Jung M.E., Kang M., Kim H.J., Kim M.J. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 2022;56 doi: 10.1016/j.bmcl.2021.128466.
29. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
30. Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
31. Günther J., Hillig R.C., Zimmermann K., Kaulfuss S., Lemos C., Nguyen D., et al. BAY-069, a Novel (Trifluoromethyl) pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe. J. Med. Chem. 2022;65(21):14366–14390. doi: 10.1021/acs.jmedchem.2c00441.
32. Sokhib Rashidov Zamon o‘g‘li, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Po‘latjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
33. Rosa J.G.S., Lima C., Lopes-Ferreira M. Zebrafish larvae behavior models as a tool for drug screenings and pre-clinical trials: A review. Int. J. Mol. Sci. 2022;23:6647. doi: 10.3390/ijms23126647.
34. Sokhib Rashidov Zamon o‘g‘li, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania.

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142

35. Sokhib Rashidov Zamon o‘g‘li, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
36. Cockerill G.S., Angell R.M., Bedernjak A., Chuckowree I., Fraser I., Gascon-Simorte J., et al. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. J. Med. Chem. 2021;64(7):3658–3676. doi: 10.1021/acs.jmedchem.0c01882.
37. Sokhib Rashidov Zamon o‘g‘li, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qo‘shbekova Ro‘zimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
38. Ortmans, S.; Daval, C.; Aguilar, M.; Compagno, P.; Cadrin-Tourigny, J.; Dyrda, K.; Rivard, L.; Tadros, R. Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts. Expert. Opin. Pharmacother. 2019, 20, 2101–2114.
39. Larson, J.; Rich, L.; Deshmukh, A.; Judge, E.C.; Liang, J.J. Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs. J. Clin. Med. 2022, 11, 3233.